mAbxience | mAbxience Sites


Fully invested platform of facilities across entire value chain, employing leading single-use bioreactor manufacturing technology:


GH Genhelix, S.A. is currently carrying out its strategic plan for the development of Bevacizumab biosimilar (monoclonal antibody), which is partially financed by the Instituto de Competitividad Empresarial de la Junta de Castilla y León with the financial support of the European Union.



Environmental Policy and Safety Policy, Mabxience León